After 2 delays, Zogenix nabs FDA approval for epilepsy drug, sets price at 3X its GW Pharma competitor
Fourteen months after refusing to file Zogenix’s first application, the FDA has approved the California biotech’s lead drug for a rare form of epilepsy called Dravet syndrome. It will be branded as Fintepla.
The company said Friday they will charge on average $96,000 for the drug — or about 3 times what GW Pharma, their main competitor, charges for their Dravet syndrome drug.
Investors have been anticipating a competition between Zogenix and GW Pharma for years. In 2018, GW won a landmark FDA approval for the first cannabinoid drug. Called Epidiolex, it had been shown in late-stage trials to reduce seizures by around 40% and represented the first approved drug for the 15,000 to 20,000 Americans with Dravet syndrome, each of whom can experience dozens of seizure per month.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,500+ biopharma pros reading Endpoints daily — and it's free.